| Literature DB >> 35162381 |
Simon Fryer1, Craig Paterson1, Lee Stoner2, Meghan A Brown1,3, James Faulkner4, Louise A Turner1, Aitor Martínez Aguirre-Betolaza5, Gabriel Zieff2, Keeron Stone1.
Abstract
Prolonged uninterrupted sitting and a typical Western meal, high in fat and refined sugar, can additively impair cognitive and cerebrovascular functions. However, it is unknown whether interrupting these behaviours, with a simple desk-based activity, can attenuate the impairment. The aim of this study was to determine whether regular leg fidgeting can off-set the detrimental effects of prolonged sitting following the consumption of a typical Western meal, on executive and cerebrovascular function. Using a randomized cross-over design, 13 healthy males consumed a Western meal and completed 180-min of prolonged sitting with leg fidgeting of 1 min on/4 min off (intervention [INT]) and without (control [CON]). Cognitive function was assessed pre and post sitting using the Trail Maker Test (TMT) parts A and B. Common carotid artery (CCA) blood flow, as an index of brain flow, was measured pre and post, and cerebral (FP1) perfusion was measured continuously. For TMT B the CON trial significantly increased (worsened) completion time (mean difference [MD] = 5.2 s, d = 0.38), the number of errors (MD = 3.33, d = 0.68) and cognitive fatigue (MD = 0.73, d = 0.92). Compared to CON, the INT trial significantly improved completion time (MD = 2.3 s, d = 0.97), and prevented declines in cognitive fatigue and a reduction in the number of errors. No significant changes in cerebral perfusion or CCA blood flow were found. Leg fidgeting for 1-min on/4-min off following a meal high in fats and refined sugars attenuated the impairment in executive function. This attenuation in executive function may not be caused by alterations in CCA blood flow or cerebral perfusion.Entities:
Keywords: cerebrovascular function; cognition; mental performance; nutrition; sedentary behaviour
Mesh:
Year: 2022 PMID: 35162381 PMCID: PMC8834958 DOI: 10.3390/ijerph19031357
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Mean (SD) glucose concentrations during the control and intervention trials.
| Mean (SD) Glucose Concentration (mmol·L−1) | |||||
|---|---|---|---|---|---|
| Pre * | Post 30 min | Post 60 min * | Post 120 min * | Post 170 min * | |
|
| 4.54 (0.38) | 6.08 (0.87) | 5.04 (0.88) | 4.81 (0.85) | 4.49 (0.50) |
|
| 4.39 (0.49) | 6.18 (0.79) | 5.06 (0.67) | 4.91 (0.67) | 4.13 (0.91) |
* = combined means are significantly (p < 0.05) different from post-30 min; CON = control trial; INT = intervention trial.
Mean (SD) measures of cognitive function (Trail Maker Part-A and Part-B), and change (Δ) in cerebral perfusion pre and post the control and intervention trials.
| Trail Maker Part-A | Trail Maker Part-B | TMT B-A | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Completion Time (s) | Number of Errors | Fatigue Score | Δ Head tHb (µmol·L−1) | Δ Head HHb (µmol·L−1) | Completion Time (s) | Number of Errors | Fatigue Score | Δ Head tHb (µmol·L−1) | Δ Head HHb (µmol·L−1) | TMT B-A (s) | |
| Mean Average (SD) | |||||||||||
|
| |||||||||||
| 0 min | 11.99 (2.05) | 0.9 (0.99) | 2.7 (1.25) | 2.13 (1.35) | −0.03 (0.58) | 15.97 (3.86) | 0.42 (0.51) | 2.64 (1.21) | 2.66 (1.17) | −0.36 (0.60) | 3.97 (4.02) |
| 180 min | 12.81 (2.72) | 2.2 (3.05) | 3.3 (1.42) | 1.33 (2.20) | −0.02 (0.81) | 21.14 (4.95) | 3.75 (4.81) | 3.36 (1.63) | 1.28 (1.63) | −0.29 (0.97) | 8.32 (4.52) |
|
| |||||||||||
| 0 min | 11.17 (1.23) | 0.3 (0.67) | 2.9 (1.29) | 1.65 (1.94) | −0.09 (0.44) | 17.52 (6.29) | 1.58 (3.20) | 3.00 (1.26) | 2.10 (1.89) | −0.37 (0.62) | 6.36 (6.41) |
| 180 min | 10.31 (0.84) | 0.6 (1.27) | 2.8 (1.48) | 1.49 (2.60) | 0.46 (0.58) | 15.27 (3.61) | 0.83 (1.34) | 2.81 (1.40) | 0.41 (1.95) | −0.01 (0.57) | 4.96 (3.53) |
|
| |||||||||||
|
| 0.067 | 0.430 | 0.111 | 0.605 | 0.090 | 0.021 * | 0.042 * | 0.049 * | 0.601 | 0.192 | 0.059 |
| ηp2 | 0.297 | 0.070 | 0.258 | 0.035 | 0.318 | 0.492 | 0.324 | 0.325 | 0.036 | 0.202 | 0.312 |
|
| |||||||||||
|
| 0.976 | 0.207 | 0.213 | 0.487 | 0.124 | 0.175 | 0.084 | 0.140 | 0.047 * | 0.291 | 0.148 |
| ηp2 | <0.001 | 0.171 | 0.167 | 0.062 | 0.185 | 0.176 | 0.246 | 0.205 | 0.409 | 0.138 | 0.197 |
|
| |||||||||||
|
| 0.049 * | 0.068 | 0.394 | 0.784 | 0.088 | 0.141 | 0.369 | 0.588 | 0.232 | 0.491 | 0.647 |
| ηp2 | 0.335 | 0.323 | 0.082 | 0.010 | 0.320 | 0.204 | 0.074 | 0030 | 0.173 | 0.061 | 0.022 |
SD = standard deviation; ηp2 = partial Eta2; p = significance; * = p < 0.05; tHb = total haemoglobin; HHb = deoxygenated haemoglobin; Δ head tHb = the difference in tHb between immediately pre and the average during the trail maker test; CON = control trial; INT = intervention trial.
Mean (SD), interaction of time × condition, and main effect of time for carotid ultrasound measures and cerebral perfusion pre (0 min) and post (180 min) the control and intervention trials.
| Carotid Blood Flow (mL·min−1) | Carotid Avg. Diameter (mm) | Carotid Velocity (m·s−1) | Cerebral Perfusion tHb (µmol·L−1) | Cerebral Perfusion HHb (µmol·L−1) | |
|---|---|---|---|---|---|
|
| |||||
|
| |||||
| 0 min | 677 (182) | 6.29 (0.27) | 39.82 (7.75) | 1.55 (1.87) | 0.44 (0.84) |
| 180 min | 613 (157) | 6.29 (0.33) | 35.1 (5.59) | −0.05 (8.99) | 1.80 (2.91) |
|
| |||||
| 0 min | 641 (186) | 6.36 (0.44) | 37.17 (9.3) | 1.74 (1.54) | 1.11 (3.14) |
| 180 min | 621 (143) | 6.32 (0.29) | 32.93 (14.67) | −2.06 (5.89) | 1.40 (4.68) |
|
| |||||
|
| 0.335 | 0.718 | 0.926 | 0.576 | 0.476 |
| ηp2 | 0.116 | 0.014 | 0.001 | 0.041 | 0.065 |
|
| |||||
|
| 0.321 | 0.724 | 0.240 | 0.108 | 0.124 |
| ηp2 | 0.123 | 0.013 | 0.149 | 0.290 | 0.269 |
|
| |||||
|
| 0.687 | 0.527 | 0.226 | 0.662 | 0.920 |
| ηp2 | 0.021 | 0.041 | 0.135 | 0.025 | 0.001 |
SD = standard deviation; ηp2 = partial Eta2; p = significance; CON = control trial; INT = intervention trial.
Mean (SD) area under the curve tHb and HHb in the head and leg during the control and intervention trials.
| CON | INT |
| Cohens’ | |
|---|---|---|---|---|
|
| 261.5 (84.7) | 200.2 (31.1) | 0.001 * | 1.392 |
|
| 207.9 (78.5) | 163.2 (72.5) | 0.011 * | 0.881 |
|
| −20.1 (74.2) | 7.2 (95.3) | 0.540 | 0.213 |
|
| 28.4 (29.5) | 18.6 (54.1) | 0.626 | 0.160 |
AUC = area under the curve; SD = standard deviation; p = significance; * = p < 0.05; CON = control trial; INT = intervention trial.